Valneva SE VALN
NASDAQ VALN
$7.00 -0.06 (-0.85%)
As of: Sep 4, 2026 · 1:38 PM EDT

Valneva SE (VALN) Cost of Revenue (2021 - 2026)

Valneva SE (VALN) posted Cost of Revenue of $30.7 million for Q1 2026, down 27.0% sequentially from $42.0 million in Q4 2025, and up 26.45% YoY from $24.2 million in Q1 2025.

Analysis

Valneva SE (VALN) Cost of Revenue (2021 - 2026) Analysis & Trends

Valneva SE has reported Cost of Revenue for 6 years, with the latest figure at $30.7 million in Q1 2026.

  • Quarterly Cost of Revenue rose 26.45% year-over-year to $30.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $127.9 million (up 19.73% YoY) and the FY2025 annual result came in at $124.7 million, up 16.94% from the prior year.
  • Cost of Revenue eased to $30.7 million in Q1 2026 per VALN's latest filing, from $42.0 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $168.2 million in Q2 2022 and troughed at $15.6 million in Q1 2022.
  • A 5-year average of $41.6 million and a median of $28.0 million in 2023 frame the typical range for Cost of Revenue.
  • The widest YoY moves for Cost of Revenue: up 593.86% in 2022, down 78.59% in 2022.
  • Over 5 years, Cost of Revenue stood at $124.2 million in 2022, then slumped by 77.42% to $28.0 million in 2023, then grew by 3.76% to $29.1 million in 2024, then soared by 44.29% to $42.0 million in 2025, then declined by 27.0% to $30.7 million in 2026.
  • According to Business Quant data, Cost of Revenue over the past three periods registered $30.7 million, $42.0 million, and $27.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Vertex Pharmaceuticals 139.26 Bn 131.41 Bn 2.84 Bn 489.20 Mn
2 Regeneron Pharmaceuticals 85.64 Bn 77.64 Bn 3.93 Bn 360.70 Mn
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn 145.00 Mn
4 Moderna 57.83 Bn 52.69 Bn 52.00 Mn 93.00 Mn
5 Revolution Medicines 44.08 Bn 44.08 Bn - -
6 BeOne Medicines 39.94 Bn 34.84 Bn 1.53 Bn 174.53 Mn
7 Alnylam Pharmaceuticals 35.19 Bn 31.88 Bn 992.69 Mn 298.26 Mn
8 Royalty Pharma 28.42 Bn 27.58 Bn - -
9 Insmed 27.35 Bn 26.19 Bn 358.27 Mn 67.21 Mn
10 Valneva SE 588.63 Mn 447.37 Mn 1.86 Mn 38.75 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 38.75 Mn
Mar 31, 2026 30.65 Mn
Dec 31, 2025 41.99 Mn
Sep 30, 2025 27.95 Mn
Jun 30, 2025 27.30 Mn
Mar 31, 2025 24.24 Mn
Dec 31, 2024 29.10 Mn
Sep 30, 2024 28.20 Mn
Jun 30, 2024 25.27 Mn
Mar 31, 2024 24.07 Mn
Dec 31, 2023 28.04 Mn
Sep 30, 2023 22.83 Mn
Jun 30, 2023 36.32 Mn
Mar 31, 2023 21.98 Mn
Dec 31, 2022 124.18 Mn
Sep 30, 2022 31.51 Mn
Jun 30, 2022 168.19 Mn
Mar 31, 2022 15.56 Mn
Dec 31, 2021 32.41 Mn
Sep 30, 2021 147.18 Mn